Why Are Overseas Registration Timelines for POCT Products Extended?

Quick Answer

The core reasons for extended overseas registration timelines for POCT (Point-of-Care Testing) products include regulatory differences in target countries leading to repeated classification and pathway confirmations, technical documentation (e.g., performance evaluation reports, clinical evidence) not meeting local requirements, quality management system certificates (e.g., ISO 13485) not covering the target country's regulatory standards, local agent or authorized representative qualifications and agreements being non-compliant, and lack of a post-market surveillance plan. Companies must first determine whether their product falls under the medical device regulatory scope of the target country (e.g., China NMPA, EU IVDR, US FDA, GHWP member states), then determine the registration pathway (self-declaration, conformity assessment, pre-market approval) based on risk classification (e.g., Class I/II/III).

Applicable Scenarios and Core Issues

When registering POCT products in multiple countries or regions simultaneously, the registration timeline often exceeds company expectations. This is particularly common in GHWP member states (e.g., China, ASEAN countries, Saudi Arabia, Brazil) and non-GHWP regions (e.g., EU, US). The core issue is that different regulatory authorities have significant differences in product classification, technical documentation requirements, clinical evidence, quality management systems (QMS), and local agent requirements, leading to repeated document preparation and review cycles.

Companies typically face the following scenarios: (1) already holding an NMPA registration certificate in China and planning to export to Southeast Asia or the Middle East; (2) having obtained CE-IVDR certification and needing to enter Latin American markets; (3) submitting applications to multiple countries simultaneously but facing document version inconsistencies due to time differences. In these scenarios, the registration timeline may extend from the expected 6 months to 12-18 months or longer.

Key stages that cause delays include classification confirmation (different countries have different risk classification rules), translation and notarization of technical documents, localization of clinical evaluation reports, recognition scope of quality management system certificates, and preparation of post-market submission requirements.

Registration Decision Logic

Step 1: Confirm Regulatory Scope

First, confirm whether the product falls under the medical device regulatory scope of the target country. For example, POCT products may be classified as "in vitro diagnostic medical devices" in some ASEAN countries (e.g., Thailand, Indonesia), while in Saudi Arabia they may be considered "medical equipment." If the regulatory classification is unclear, companies must submit an inquiry letter to the local regulatory authority, which can take 1-3 months.

Step 2: Determine Risk Class and Registration Pathway

According to the IMDRF classification system, POCT products are typically classified into Class II or Class III based on test items (e.g., infectious diseases, hormones, tumor markers). Classification mapping varies by country: Under the EU IVDR, self-testing POCT products are Class D and require Notified Body review; the US FDA requires 510(k) or PMA. Different pathways lead to significantly different timelines.

Step 3: Assess Reusability of Existing Documentation

Evaluate whether existing NMPA or CE documentation (e.g., performance evaluation reports, clinical study reports, risk management files) is acceptable in the target country. For example, Brazil ANVISA requires technical files to include local epidemiological data, and Chinese data is generally not directly accepted; Thailand FDA may accept English CE files but requires supplementary local laboratory verification. Companies are advised to build a "core document package" in advance, containing product description, intended use, performance specifications, stability data, analytical performance reports, clinical evidence summary, risk management report (ISO 14971), and labels and instructions for use (in English and the target country's language).

Step 4: Confirm QMS Requirements

Most countries require manufacturers to hold an ISO 13485 certificate, but some countries (e.g., Saudi Arabia, UAE) also require compliance with local additional standards (e.g., SASO). If the certificate does not cover the target country, a gap analysis and supplementary audit are needed, typically taking 3-6 months.

Step 5: Appoint a Local Agent or Authorized Representative

Almost all countries require overseas manufacturers to appoint a local agent responsible for submitting applications, communicating with regulatory authorities, and post-market surveillance. The agent's qualifications and agreement content directly affect registration efficiency. Common pitfalls include agents lacking local registration experience and contracts not clearly defining responsibilities for changes and renewals.

Technical Documentation and Evidence

Key evidence in technical files includes: product performance evaluation reports (precision, accuracy, linear range, interference studies); stability data (accelerated and real-time); clinical evaluation reports (CER) or clinical study reports (CSR) that meet local clinical evidence requirements. For example, India's CDSCO requires at least 200 local clinical samples, while Malaysia's MDA may accept overseas clinical data.

Risk management files must comply with ISO 14971:2019 and include risk analysis specific to the target country's use conditions (e.g., operator language differences, transport conditions). Labels and instructions for use must meet local language and regulatory requirements, such as Arabic labels for Saudi SFDA, Portuguese instructions for Brazil ANVISA, and require third-party translation and notarization.

QMS evidence includes the ISO 13485 certificate and the latest audit report; an MDSAP certificate (if available) can speed up multi-country registration, but coverage of the target country must be verified. Post-market surveillance documents include a PMS plan, PSUR reports, and complaint handling procedures. Companies should maintain complete change history records to respond to local drug administration inquiries.

Common Mistakes

• Directly transferring domestic or CE files without conducting a target-country regulatory gap analysis, leading to increased deficiency corrections.
• Inappropriate local agent selection: agents without clinical evaluation or technical document review experience cannot effectively guide registration.
• Ignoring label and IFU localization: only translating key information without considering local cultural practices and specific regulatory requirements (e.g., warning statement placement, symbol usage).
• Inadequate clinical evidence: when overseas data is not accepted, failing to initiate local clinical trials promptly, causing project stagnation.
• QMS certificate not updated or covering the product: ISO 13485 certificate expired without renewal, or the certification scope does not include POCT products.
• No post-market surveillance system: inability to submit annual reports or adverse event reports after registration, leading to certificate suspension.

Enterprise Preparation Checklist

• Target country regulatory database or gap analysis report (clarifying classification, pathway, requirements).
• Core technical document package (in English, including performance, risk, clinical, stability, labeling).
• QMS certificate and scope list (ISO 13485 + MDSAP or other locally recognized certificates).
• Local agent candidate list and qualification review form.
• Label and IFU translation and notarization plan (with timelines).
• Clinical evidence strategy: determine whether local data is needed or overseas data is acceptable, and the corresponding budget.
• Multi-country registration timeline (including key milestones: submission, deficiency response, review, approval).

AIMEILI Regulatory Interpretation and Business Impact

Companies often incorrectly assume that "NMPA or CE documentation is universally accepted," but in reality, each country has unique regulatory requirements. AIMEILI recommends spending 2-4 weeks in the early project phase conducting a GAP analysis to benchmark the target country's classification, technical documentation, clinical evidence, QMS, and agent requirements. For document reuse, ISO 14971 risk management reports and performance summaries can be leveraged, but clinical evaluation must incorporate local epidemiological or verification data. Local agent selection is critical: agents should not only handle submissions but also provide regulatory interpretation and feedback capabilities. Keep control in your hands: the manufacturer should be the certificate holder, and the agent is only a representative.

In change and renewal contracts, clearly define responsibilities to avoid registration certificate invalidation when changing agents. For multi-country registration, organize a core document package uniformly and add localization annotations per country requirements to reduce duplicate preparation and deficiency risks. Do not wait for deficiency notices—proactive preparation can shorten the timeline by 30%-50%.

Frequently Asked Questions

Q1: What if the target country does not have a clear classification for POCT products?

A: Refer to IMDRF guidelines or precedents for similar products in that country. If still unclear, submit a classification consultation letter to the regulatory authority while preparing risk class assumptions and corresponding evidence. Reserve 2-3 months for this process. Do not self-declare a low risk and skip Notified Body review, as this may lead to rejection.

Q2: Can a single risk analysis report be shared for multi-country registration?

A: Core risk analysis (e.g., ISO 14971 report) can be shared, but you must add risks specific to each target country, such as transport conditions, use environment, and intended user language differences. We recommend creating a "country-specific risk appendix" to supplement analysis for different regions, allowing you to reuse the core file while satisfying local requirements.

Q3: Must post-market surveillance documents be prepared during the registration stage?

A: Yes. Most countries require a PMS plan (including a PMPF plan under the EU IVDR) to be submitted during the application phase. Companies should prepare the PMS plan document, complaint handling procedures, and a product history review (e.g., PSUR template). Missing these documents can cause review delays or rejection.